ArticlePloS one2012

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.

Filipa Aragão et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.